Investigation of the association between the MDM2 T309G polymorphism and gastric cancer

Tas,Ayca; Atabey,Mustafa; Caglayan,Gulcin; Bostanci,Meric Emre; Sahin Bolukbasi,Serap; Topcu,Omer; Silig,Yavuz

doi:10.3892/br.2017.978

Investigation of the association between the MDM2 T309G polymorphism and gastric cancer

Authors:
- Ayca Tas
- Mustafa Atabey
- Gulcin Caglayan
- Meric Emre Bostanci
- Serap Sahin Bolukbasi
- Omer Topcu
- Yavuz Silig
View Affiliations

Affiliations: Department of Nutrition and Diet, Cumhuriyet University, Faculty of Health Sciences, 58140 Sivas, Turkey, Department of General Surgery, Cumhuriyet University, Faculty of Medicine, 58140 Sivas, Turkey, Department of Biochemistry, Cumhuriyet University, Faculty of Medicine, 58140 Sivas, Turkey, Clinic of General Surgery, Sivas Sample Hospital, 58060 Sivas, Turkey, Department of Biochemistry, Cumhuriyet University, Faculty of Pharmaceutics, 58140 Sivas, Turkey
Published online on: September 11, 2017 https://doi.org/10.3892/br.2017.978
Pages: 469-473

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Murine double minute clone 2 oncoprotein (MDM2) is a key component in the regulation of the tumour suppressor p53. The association between the MDM2 polymorphism and gastric cancer (GC) has been investigated in Turkish population. In the present case‑control study, the aim was to investigate the association between genetic polymorphisms of the MDM2 gene (a major regulator of p53 function) and primary GC risk in a Turkish population. The polymorphism, T309G (rs2279744) in the MDM2 gene was determined in patients with GC (n=65) and in healthy control subjects (n=67) using the polymerase chain reaction‑restriction fragment length polymorphism method. The findings were evaluated using logistic regression and χ2 tests. No statistically significant differences were observed between the control subjects and patients with GC regarding smoking status. A comparison between GC cases and control subjects indicated a statistically significant difference for family history of cancer [odds ratio (OR)=0.17; 95% confidence interval (CI), 0.05‑0.56; χ2=0.19; P=0.01]. A significant difference was identified in the GG genotype distribution between GC patients and control subjects (OR=4.58; 95% CI, 1.18‑17.79; P=0.022). Thus, the results of the present study indicate that the MDM2 gene T309G intron (GG) genotype may be an important risk factor for GC development in the Turkish population.

View Figures

View References

1	McBride OW, Merry D and Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA. 83:130–134. 1986. View Article : Google Scholar : PubMed/NCBI
2	Strachan T and Read AP: Human molecular genetics. 2nd. Wiley-Liss; New York, NY: 1999, PubMed/NCBI
3	Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Watanabe M, Ito S, Sawaki A, Iida S, Sato S, et al: ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev. 20:1665–1672. 2011. View Article : Google Scholar : PubMed/NCBI
4	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
5	Marte B: Cancer: Super p53. Nature. 420:2792002. View Article : Google Scholar : PubMed/NCBI
6	Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K and Yamanaka S: Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 460:1132–1135. 2009. View Article : Google Scholar : PubMed/NCBI
8	Misra C, Majumder M, Bajaj S, Ghosh S, Roy B and Roychoudhury S: Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog. 48:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
9	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI
10	Honda R, Tanaka H and Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27. 1997. View Article : Google Scholar : PubMed/NCBI
11	Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature. 387:299–303. 1997. View Article : Google Scholar : PubMed/NCBI
12	Momand J and Zambetti GP: Mdm-2: ‘big brother’ of p53. J Cell Biochem. 64:343–352. 1997. View Article : Google Scholar : PubMed/NCBI
13	Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
14	Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D'Andrea E, et al: Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst. 98:285–288. 2006. View Article : Google Scholar : PubMed/NCBI
15	Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y and Goto H: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol. 24:4434–4440. 2006. View Article : Google Scholar : PubMed/NCBI
16	Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim DY, Chon CY and Han KH: MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 29:1192–1196. 2008. View Article : Google Scholar : PubMed/NCBI
17	Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI
18	Yilmaz M, Tas A, Kacan T, Sari M and Silig Y: Is there a relation between murine double minute 2 T309G polymorphism and lung cancer risk in the Turkish population? Turk J Biochem. 42:123–129. 2017.
19	Crew KD and Neugut AI: Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 31:450–464. 2004. View Article : Google Scholar : PubMed/NCBI
20	Geng JS, Song HT and Wang WR: Diversity of invasiveness and matrix metalloproteinases expression profile of human gastric carcinoma xenografted in different tissue environments. Zhonghua Bing Li Xue Za Zhi. 33:53–56. 2004.(In Chinese). PubMed/NCBI
21	Brady M, Vlatkovic N and Boyd MT: Regulation of p53 and MDM2 activity by MTBP. Mol Cell Biol. 25:545–553. 2005. View Article : Google Scholar : PubMed/NCBI
22	Freedman DA, Wu L and Levine AJ: Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 55:96–107. 1999. View Article : Google Scholar : PubMed/NCBI
23	Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y and Dahiya R: MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 13:4123–4129. 2007. View Article : Google Scholar : PubMed/NCBI
24	Terry K, McGrath M, Lee IM, Buring J and De Vivo I: MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 17:983–986. 2008. View Article : Google Scholar : PubMed/NCBI
25	Olsson H, Hultman P, Rosell J, Söderkvist P and Jahnson S: MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol. 13:52013. View Article : Google Scholar : PubMed/NCBI
26	Zhang GX, Li YQ and Pan XL: Polymorphism of MDM2 promoter, regulated by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility to gastric carcinoma and poor prognosis in Chinese patients. J Gastroenterol Hepatol. 26:2802011.
27	Wang X, Yang J, Ho B, Yang Y, Huang Z, Zhang Z and Zhang G: Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter. 14:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
28	Cho YG, Choi BJ, Song JH, Kim CJ, Cao Z, Nam SW, Lee JY and Park WS: No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma. 55:256–260. 2008.PubMed/NCBI
29	Pan X, Li Y, Feng J, Wang X, Hao B, Shi R and Zhang G: A functional polymorphism T309G in MDM2 gene promoter, intensified by Helicobacter pylori lipopolysaccharide, is associated with both an increased susceptibility and poor prognosis of gastric carcinoma in Chinese patients. BMC Cancer. 13:1262013. View Article : Google Scholar : PubMed/NCBI
30	Chen W, Wu Q and Ren H: Meta-analysis of associations between MDM2 SNP309 polymorphism and gastric cancer risk. Biomed Rep. 2:105–111. 2014. View Article : Google Scholar : PubMed/NCBI
31	Er LM, Zhang LW, Niu WW, Xu ZB, Du CQ, Gao Y, Wang SP and Yuan L: Relation of MDM2 gene polymorphism and Helicobacter pylori infection to gastric cardiac carcinoma. Lin Chuang Hui Cui. 24:1594–1597. 2009.(In Chinese).
32	Tian X, Tian Y, Ma P, Sui C-G, Meng F-D, Li Y, Fu L-Y, Jiang T, Wang Y, Ji FJ, et al: Association between MDM2 SNP309 T>G and risk of gastric cancer: A meta-analysis. Asian Pac J Cancer Prev. 14:1925–1929. 2013. View Article : Google Scholar : PubMed/NCBI
33	Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, Zhao D, Yu D, Liu J and Lin D: Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 28:1996–2001. 2007. View Article : Google Scholar : PubMed/NCBI